|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Forced expiratory volume function
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries.
|
30804560 |
2019 |
|
Vital capacity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries.
|
30804560 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Low density lipoprotein cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program.
|
30275531 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Septicemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The use of assembly algorithms, such as SGB, for the generation of a customized model for sepsis yields more accurate 1-year mortality prediction than the traditional scoring systems such as SAPS II, SOFA or OASIS.
|
30245121 |
2020 |
|
Sepsis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The use of assembly algorithms, such as SGB, for the generation of a customized model for sepsis yields more accurate 1-year mortality prediction than the traditional scoring systems such as SAPS II, SOFA or OASIS.
|
30245121 |
2020 |
|
Septicemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Against the observed in-hospital mortality of 30.2%, SAPS 2 showed a weak performance with a predicted mortality of 17.4% and a SMR of 1.74 (95% CI, 1.38-2.09), especially in association with liver diseases and/or sepsis.
|
31553738 |
2019 |
|
Sepsis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Against the observed in-hospital mortality of 30.2%, SAPS 2 showed a weak performance with a predicted mortality of 17.4% and a SMR of 1.74 (95% CI, 1.38-2.09), especially in association with liver diseases and/or sepsis.
|
31553738 |
2019 |
|
Septicemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
NALP1 mRNA levels were linked to survival in patients with sepsis (P = 0.0068) and correlated with SAPS II scores (r = -0.63).
|
18263805 |
2008 |
|
Sepsis
|
0.030 |
Biomarker
|
disease |
BEFREE |
NALP1 mRNA levels were linked to survival in patients with sepsis (P = 0.0068) and correlated with SAPS II scores (r = -0.63).
|
18263805 |
2008 |
|
End Stage Liver Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the decision curve analysis, the net benefit of implementing CLIF-SOFA and CLIF-C OF to predict the prognosis of cirrhotic patients with suspected infection were higher compared with SIRS, qSOFA, MELD, or qCLIF-SOFA.CLIF-SOFA and CLIF-C OF scores, as well as SAPS II were better tools than SIRS, qSOFA, MELD, or qCLIF-SOFA to evaluate the prognosis of critically ill cirrhotic patients with suspected infection.
|
29995791 |
2018 |
|
End Stage Liver Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Domino and deceased donor recipients had similar preoperative severity indices (Child-Pugh classification and Model for End-Stage Liver Disease score) and immediate postoperative severity scores (APACHE II [Acute Physiology and Chronic Health Evaluation II] and SAPS II [Simplified Acute Physiology Score II]).
|
21384509 |
2011 |
|
Liver diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In contrast, the SAPS 2 underestimated mortality particularly in patients with liver diseases and sepsis.
|
31553738 |
2019 |
|
Myasthenia Gravis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
OP-MG myocytes compared to control MG myocytes showed altered expression of four OP-MG susceptibility genes (PPP6R2, CANX, FAM136A and FAM69A) as well as several MG and EAMG genes (p < 0.05).
|
30696470 |
2019 |
|
Ophthalmoplegia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
OP-MG myocytes compared to control MG myocytes showed altered expression of four OP-MG susceptibility genes (PPP6R2, CANX, FAM136A and FAM69A) as well as several MG and EAMG genes (p < 0.05).
|
30696470 |
2019 |
|
Status Epilepticus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To characterize a critically ill cohort with status epilepticus (SE) by the illness severity scoring systems SAPS II (Simplified Acute Physiology Score II), APACHE II (Acute Physiology and Chronic Health Evaluation II), and SOFA (Sequential Organ Failure Assessment), and to compare their performance with the STESS (Status Epilepticus Severity Score) for outcome prediction.
|
30585317 |
2019 |
|
Abdominal Infection
|
0.010 |
Biomarker
|
group |
BEFREE |
However, after adjusting for confounders (i.e., SAPS II and septic shock at IAI diagnosis, ICU-acquired peritonitis, and adequacy of IAT for other germs), the impact of the adequacy of IAT was no longer significant in multivariate analysis.
|
31492201 |
2019 |
|
Respiratory Failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In total, 201 ICU patients' recordings (SAPS II 51.7 ± 34.6) were analysed during the retrospective evaluation phase, most of them being admitted for a respiratory failure and requiring invasive mechanical ventilation.
|
30666472 |
2019 |
|
Kidney Failure, Acute
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The equations MAP-IAP-Pmean (1-area under the curve [AUC]: 0.796; likelihood ratio [LR]+: 3.520; LR-: 0.337; p < 0.01), MAP-IAP-CVP-Pmean (1-AUC: 0.794; LR+: 2.743; LR-: 0.282; p < 0.01), and MAP-2 × IAP-CVP-Pmean (1-AUC: 0.791; LR+: 4.321; LR-: 0.262; p < 0.001) showed small to moderate effect on AKI but have better performance than severity score systems (SAPS II [AUC: 0.696; LR+: 3.143, LR-: 0.433; p < 0.01], SOFA [AUC: 0.717; LR+: 2.089; LR-: 0.528; p < 0.001]).
|
29614507 |
2018 |
|
Neck stiffness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
By multivariable Cox model, SAPS II [hazard-ratio (HR) = 1.03 (1.02-1.04); p < 0.001], lower leucocytes [HR 0.83 (0.69-0.99); p = 0.034] and platelet counts [HR 0.77 (0.60-0.91); p = 0.007], and arterial blood lactate levels [HR 2.71 (1.68-4.38); p < 0.001] were independently associated with hospital death, while a neck stiffness [HR 0.51 (0.28-0.92); p = 0.026] was a protective factor.
|
30128591 |
2018 |
|
Systemic Inflammatory Response Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the decision curve analysis, the net benefit of implementing CLIF-SOFA and CLIF-C OF to predict the prognosis of cirrhotic patients with suspected infection were higher compared with SIRS, qSOFA, MELD, or qCLIF-SOFA.CLIF-SOFA and CLIF-C OF scores, as well as SAPS II were better tools than SIRS, qSOFA, MELD, or qCLIF-SOFA to evaluate the prognosis of critically ill cirrhotic patients with suspected infection.
|
29995791 |
2018 |
|
Acute respiratory failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Survival was associated with acute respiratory failure (48% vs 19%, P = .006), a history of COPD (40% vs 21%, P = .03) and a lower SAPS II score (44 vs 49, P = .006).
|
29660241 |
2018 |
|
Primary infection NOS
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collected data included the demographic characteristics of the patients, the diagnosis at admission, SOFA, SAPS II and Murray Lung Injury Score (LIS), characteristics of the primary infection, the adequacy of antimicrobial therapy, the delay of administration of ivIgGAM from the ICU admission and the outcome at the ICU discharge.
|
30535962 |
2018 |